secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001437749-25-006457
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027
-------------------------------------------------------------------------------

- Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).
- Cash and equivalents $204.8M at Dec 31, 2024; expects to fund operations through 2027.
- Topline data from PIPE-791 Phase 1b PET trial expected Q2 2025; PIPE-307 Phase 2 RRMS data H2 2025.
- PIPE-791 Phase 2 proof-of-concept in IPF and PrMS planned H2 2025 pending toxicity studies.
- Plan to file IND for CTX-343 in H2 2025; J&J recruiting Phase 2 MDD trial of PIPE-307.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/0001437749-25-006457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/cont20250214_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer